Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21334004 | 1.00 | KMT2A (0.43) | KMT2ACYP2D6KDM4ECCR5OPRM1 | |
| SCHEMBL20594755 | 1.00 | KMT2A (0.43) | KMT2ACYP2D6KDM4ECCR5OPRM1 | |
| SCHEMBL20594447 | 1.00 | KMT2A (0.43) | KMT2ACYP2D6KDM4ECCR5OPRM1 | |
| SCHEMBL21334003 | 1.00 | KMT2A (0.43) | KMT2ACYP2D6KDM4ECCR5OPRM1 | |
| SCHEMBL20594448 | 1.00 | KMT2A (0.43) | KMT2ACYP2D6KDM4ECCR5OPRM1 | |
| SCHEMBL21338814 | 0.86 | CYP1A2 (0.48) | KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL16671440 | 0.86 | CYP1A2 (0.48) | KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL21338822 | 0.86 | CYP1A2 (0.48) | KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL22053384 | 0.86 | CYP1A2 (0.48) | KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL3614301 | 0.86 | CYP1A2 (0.48) | KMT2ACYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-10377709-B2 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-08-13 | — | — | US | disclosed |
| US-20190002406-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-01-03 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20180065929-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-03-08 | — | — | US | disclosed |
| EP-3060547-B1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-11 | — | — | EP | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9567299-B2 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-14 | — | — | US | disclosed |
| US-20160264522-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2016-09-15 | — | — | US | disclosed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002406-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, XDH, NR1H4 | KMT2A 1461/4885CYP2D6 324/4885KDM4E 1093/4885 |
| US-20180065929-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, NR1H4, GLS2 | KMT2A 1413/4885CYP2D6 220/4885KDM4E 985/4885 |
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | KMT2A 2365/4885CYP2D6 614/4885KDM4E 1187/4885 |
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | KMT2A 280/4885CYP2D6 2375/4885KDM4E 175/4885 |
| US-10377709-B2 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HCCS, XDH, NR1H4 | KMT2A 1461/4885CYP2D6 324/4885KDM4E 1093/4885 |
| US-20160264522-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, XDH, NR1H4 | KMT2A 1461/4885CYP2D6 324/4885KDM4E 1093/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | KMT2A 280/4885CYP2D6 2375/4885KDM4E 175/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | KMT2A 280/4885CYP2D6 2375/4885KDM4E 175/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | KMT2A 313/4885CYP2D6 2710/4885KDM4E 178/4885 |
| US-20190330202-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | KMT2A 313/4885CYP2D6 2710/4885KDM4E 178/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | KMT2A 313/4885CYP2D6 2710/4885KDM4E 178/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | KMT2A 313/4885CYP2D6 2710/4885KDM4E 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.